**Author details**

Franc Llorens1,2\*, Anna Villar-Piqué<sup>2</sup> , Niccolò Candelise<sup>2</sup> , Isidre Ferrer1,4 and Inga Zerr2,3

is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. The Journal of Biological Chemistry. 2012;**287**:3842-3849. DOI: 10.1074/jbc.M111.277061 [9] Dujardin S, Bégard S, Caillierez R, Lachaud C, Delattre L, Carrier S, Loyens A, Galas MC, Bousset L, Melki R, Aurégan G, Hantraye P, Brouillet E, Buée LM. Colin, Ectosomes: A new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;**9**. DOI:

Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias

http://dx.doi.org/10.5772/intechopen.73528

81

[10] Chai X, Dage JL, Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiology of Disease. 2012;**48**:356-366. DOI: 10.1016/j.nbd.2012.05.021

[11] Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews. Neuroscience. 2007;**8**:663-672. DOI:

[12] Kovacs GG. Invited review: Neuropathology of tauopathies: Principles and practice. Neuropathology and Applied Neurobiology. 2015;**41**:3-23. DOI: 10.1111/nan.12208 [13] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2011;**1**. DOI: 10.1101/

[14] Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology.

[15] Lewczuk P, Lelental N, Lachmann I, Holzer M, Flach K, Brandner S, Engelborghs S, Teunissen CE, Zetterberg H, Molinuevo JL, Mroczko B, Blennow K, Popp J, Parnetti L, Chiasserini D, Perret-Liaudet A, Spitzer P, Maler JM, Kornhuber J. Non-phosphorylated tau as a potential biomarker of Alzheimer's disease: Analytical and diagnostic characterization. Journal of Alzheimer's Disease. 2016;**55**:159-170. DOI: 10.3233/JAD-160448 [16] Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, Varges D, Schmidt C, Zerr I, Stoeck K. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimer's & Dementia. 2016;**12**:577-589.

[17] Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, Van De Ven PM, Pijnenburg YAL, Blankenstein MA, Rozemuller AJ, Scheltens P, Van Der Flier WM. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory

[18] Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the consensus

clinic cohort. Neurology. 2012;**78**:47-54. DOI: 10.1212/WNL.0b013e31823ed0f0

2003;**2**:605-613. DOI: 10.1016/S1474-4422(03)00530-1

10.1371/journal.pone.0100760

10.1038/nrn2194

cshperspect.a006189

DOI: 10.1016/j.jalz.2015.10.009

\*Address all correspondence to: franc.llorens@gmail.com

1 Network Center for Biomedical Research in Neurodegenerative Diseases, (CIBERNED), Institute Carlos III, Ministry of Health, Barcelona, Spain

2 Department of Neurology, University Medical Center Goettingen, Göttingen, Germany

3 Germany and German Center for Neurodegenerative Diseases (DZNE), Góttingen, Germany

4 Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, University of Barcelona, Hospitalet de Llobregat, Spain
